

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

**APPOINTMENT OF CHAIRMAN, CHIEF EXECUTIVE OFFICER,
HOSPITAL CHIEF EXECUTIVE AND
INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board wishes to announce that with effect from 11 December 2017:

- (1) Mr. Zhang Fan, the executive Director, has been appointed as chairman of the Company;
- (2) Mr. Chung Ho, the executive Director, has been appointed as chief executive officer of the Company;
- (3) Mr. Wang Jingming, the executive Director, has been appointed as hospital chief executive of the Group; and
- (4) Mr. Du Yanhua has been appointed as an independent non-executive Director.

**APPOINTMENT OF CHAIRMAN, CHIEF EXECUTIVE OFFICER AND HOSPITAL
CHIEF EXECUTIVE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from 11 December 2017, (i) Mr. Zhang Fan, the executive Director, has been appointed as chairman of the Company; (ii) Mr. Chung Ho, the executive Director, has been appointed as chief executive officer of the Company; and (iii) Mr. Wang Jingming, the executive Director, has been appointed as hospital chief executive of the Group.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that Mr. Du Yanhua (“**Mr. Du**”) has been appointed as an independent non-executive Director with effect from 11 December 2017.

Mr. Du Yanhua, aged 51, graduated from Wuhan University with a Bachelor degree in Virology and a Master degree in Radio Biophysics. He specializes in fields of biophysics, radiation biology and medicine, HIV/SIV vaccine design and construction, laboratory and primates animal immunization, drug and vaccine manufacture, verification of vaccine and clinical trials declaration. He was a research assistant and a lecturer from in College of Life Sciences, Wuhan University from 1987 to 1992 and from 1992 to 2006 respectively. He worked as researcher and engineer in Zheng Tai Technical & Trade Limited in Wuhan from 2001 to 2005. He was also a visiting research scholar in The Aaron Diamond AIDS Research Center, New York from 2006 to 2008 and a research assistant in Aids Institute, LKS Faculty of Medicine in The University of Hong Kong from 2008 to 2012. He has been a technical manager in the Aids Institute, LKS Faculty of Medicine in The University of Hong Kong since March 2012, a senior project manager of Immuno Cure Limited since May 2015 and the chief executive officer of Shenzhen Yike Bio-technical Limited since October 2017.

There is no service contract between Mr. Du and the Company. Mr. Du has not been appointed for any fixed term but will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The remuneration of Mr. Du will be determined by the Remuneration Committee of the Company subsequently which will be on the basis of his duties and responsibilities within the Company and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, (i) Mr. Du does not hold any other position in the Company or its subsidiaries; (ii) Mr. Du does not hold any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) Mr. Du does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance; (iv) Mr. Du does not have any relationship with any directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) or controlling shareholders (as defined in the Listing Rules) of the Company; and (v) Mr. Du has not possessed any other professional qualifications.

Mr. Du has confirmed that he has met the independence criteria as set out in Rule 3.13 of the Listing Rules and there are no matters that are required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that needed to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Du to join the Board.

The number of independent non-executive Directors falls below the minimum number required under Rule 3.10A of the Listing Rules upon change of directors on 25 July 2017. Following appointment of Mr. Du as an independent non-executive Director, the Company has fulfilled the requirement under Rule 3.10A of the Listing Rules.

By order of the Board
China Health Group Limited
Weng Yu
Executive Director

Hong Kong, 11 December 2017

As at the date of this announcement, the Board comprises five executive Directors, namely, Mr. Weng Yu, Mr. Wang Yongqing, Mr. Chung Ho, Mr. Wang Jingming and Mr. Zhang Fan; eight non-executive Directors, namely, Mr. Ying Wei, Mr. Zhang Song, Mr. Xing Yong, Mr. Wang Zili, Mr. Wang Yuexiang, Mr. Li Xuguang, Mr. Ma Zhaorui and Mr. Huang Lianhai; and seven independent non-executive Directors, namely, Mr. Xiao Zuhe, Mr. Wang Qingyou, Mr. Zou Lian, Ms. Yang Huimin, Mr. Xin Hua, Mr. Jiang Xuejun and Mr. Du Yanhua.